Alemtuzumab dose and serum concentrations: subcutaneous study
Patient no. . | Cumulative dose, mg . | No. of samples . | Above LOQ . | Terminal samples . | Dose to reach 1 μg/mL . | Max concentration, μg/mL . | After last dose, μg/mL . |
|---|---|---|---|---|---|---|---|
| 8010 | 1358 | 24 | 2 | 0 | 728 | 1.3 | ND |
| 8015 | 1506 | 28 | 1 | 0 | > 156 | 0.6 | ND |
| 8016 | 1573 | 29 | 3 | 0 | 673 | 1.5 | ND |
| 8017 | 1213 | 20 | 2 | 0 | > 193 | 0.9 | ND |
| 8021 | 983 | 29 | 12 | 3 | 353 | 5.3 | 4.1 |
| 8026 | 1379 | 23 | 3 | 0 | 959 | 1.4 | ND |
| 8027 | 1269 | 43 | 9 | 1 | 639 | 9.0 | 6.8 |
| 8028 | 1363 | 37 | 13 | 3 | 403 | 5.8 | 5.8 |
| 8029 | 1133 | 34 | 9 | 1 | 503 | 7.3 | 7.3 |
| 8030 | 1553 | 45 | 16 | 1 | 473 | 4.3 | 4.2 |
| 8031 | 712 | 27 | 2 | 1 | 712 | 1.4 | 1.4 |
| 8032 | 723 | 17 | 2 | 0 | 393 | 2.5 | 2.5 |
| 8033 | 1302* | 28 | 10 | 0 | 542 | 3.4 | 3.0 |
| 8034 | 1412 | 24 | 16 | 4 | 269 | 6.3 | 5.8 |
| 8035 | 1036 | 24 | 15 | 6 | 406 | 17.1 | 17.1 |
| 8036 | 819* | 21 | 0 | 0 | > 819 | < 0.5 | < 0.5 |
| 8038 | 1486 | 19 | 9 | 3 | 1106 | 2.6 | 2.6 |
| 8039 | 1526 | 19 | 10 | 0 | 596 | 4.4 | ND |
| 8040 | 1496 | 26 | 19 | 7 | 146 | 24.8 | 24.8 |
| 8041 | 852 | 23 | 6 | 0 | 462 | 3.5 | 3.5 |
| Minimum | 712 | 17 | 0 | 0 | 146 | 0.6 | < 0.5 |
| Mean | 1249 | 27 | 8 | 1.5 | 551 | 5.4 | 6.4 |
| Maximum | 1573 | 45 | 19 | 7 | 1106 | 24.8 | 24.8 |
Patient no. . | Cumulative dose, mg . | No. of samples . | Above LOQ . | Terminal samples . | Dose to reach 1 μg/mL . | Max concentration, μg/mL . | After last dose, μg/mL . |
|---|---|---|---|---|---|---|---|
| 8010 | 1358 | 24 | 2 | 0 | 728 | 1.3 | ND |
| 8015 | 1506 | 28 | 1 | 0 | > 156 | 0.6 | ND |
| 8016 | 1573 | 29 | 3 | 0 | 673 | 1.5 | ND |
| 8017 | 1213 | 20 | 2 | 0 | > 193 | 0.9 | ND |
| 8021 | 983 | 29 | 12 | 3 | 353 | 5.3 | 4.1 |
| 8026 | 1379 | 23 | 3 | 0 | 959 | 1.4 | ND |
| 8027 | 1269 | 43 | 9 | 1 | 639 | 9.0 | 6.8 |
| 8028 | 1363 | 37 | 13 | 3 | 403 | 5.8 | 5.8 |
| 8029 | 1133 | 34 | 9 | 1 | 503 | 7.3 | 7.3 |
| 8030 | 1553 | 45 | 16 | 1 | 473 | 4.3 | 4.2 |
| 8031 | 712 | 27 | 2 | 1 | 712 | 1.4 | 1.4 |
| 8032 | 723 | 17 | 2 | 0 | 393 | 2.5 | 2.5 |
| 8033 | 1302* | 28 | 10 | 0 | 542 | 3.4 | 3.0 |
| 8034 | 1412 | 24 | 16 | 4 | 269 | 6.3 | 5.8 |
| 8035 | 1036 | 24 | 15 | 6 | 406 | 17.1 | 17.1 |
| 8036 | 819* | 21 | 0 | 0 | > 819 | < 0.5 | < 0.5 |
| 8038 | 1486 | 19 | 9 | 3 | 1106 | 2.6 | 2.6 |
| 8039 | 1526 | 19 | 10 | 0 | 596 | 4.4 | ND |
| 8040 | 1496 | 26 | 19 | 7 | 146 | 24.8 | 24.8 |
| 8041 | 852 | 23 | 6 | 0 | 462 | 3.5 | 3.5 |
| Minimum | 712 | 17 | 0 | 0 | 146 | 0.6 | < 0.5 |
| Mean | 1249 | 27 | 8 | 1.5 | 551 | 5.4 | 6.4 |
| Maximum | 1573 | 45 | 19 | 7 | 1106 | 24.8 | 24.8 |
Some doses for patients no. 8033 and no. 8036 were given intravenously due to infusion site reactions during the subcutaneous administration.